YMAB - Y-mAbs Therapeutics Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information
Boston, Massachusetts--(Newsfile Corp. - January 20, 2023) - Block & Leviton announces that a class action lawsuit has been filed against Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) for securities law violations. Investors who purchased shares and have lost money are encouraged to contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/ymab.
What is this all about?
On October 26, 2022, briefing documents posted to the U.S. Food and Drug Administration (FDA) website identified concerns by FDA scientists regarding data submitted by Y-mAbs Therapeutics, Inc. in support of the company's Biologics License Application (BLA) for its neuroblastoma therapy, omburtamab.
Key issues identified by the FDA include differences between study and control populations and their impact on the control population as a comparator, results from FDA conducted analyses to examine bias, and a lack of reliable response rate data for supportive evidence of the treatment effect of omburtamab.
Previously, on April 1, 2022, Y-mAbs Therapeutics resubmitted its BLA for omburtamab after the FDA issued a Refuse to File letter regarding the company's marketing application for the drug in children with CNS/leptomeningeal metastasis from neuroblastoma, citing portions of two modules in the application requiring further detail.
Shares of Y-mAbs Therapeutics, Inc. stock dropped more than 20% in intraday trading on October 26, 2022.
Who is eligible?
Anyone who purchased Y-mAbs Therapeutics, Inc. stock between October 6, 2020 and October 28, 2022, whether or not they have sold their investment. Investors should contact Block & Leviton to learn more.
What should you do next?
The deadline to seek appointment as lead plaintiff is March 20, 2023. A class has not yet been certified, and until a certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
If you've lost money on your investment, you should contact Block & Leviton to learn more via our case website, by email at cases@blockleviton.com, or by phone at (617) 398-5600.
Why should you contact Block & Leviton?
Many law firms have issued releases about this matter; most of those firms do not actually litigate securities class actions. Block & Leviton is a law firm that actually litigates cases. We are dedicated to obtaining significant recoveries on behalf of defrauded investors through active litigation in the federal courts across the country. Many of the nation's top institutional investors hire us to represent their interests. You can learn more about us at our website, www.blockleviton.com, or call (617) 398-5600 or email cases@blockleviton.com with any questions.
This notice may constitute attorney advertising.
CONTACT:
BLOCK & LEVITON LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (617) 398-5600
Email: cases@blockleviton.com
SOURCE: Block & Leviton LLP
www.blockleviton.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/152005